This report contains detailed information about the company's business finances and management.
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 56.80 | 0.06 0.11% | 3.10% | 10,140,975 | 8.3M |
------- ------- ------- ------- ------- ------- ------- ------- ------- ---- ---- TOTAL SALES (1) $10,264 $10,934 $21,198 $10,671 $11,010 $21,681 $11,032 $11,319 $44,033 -1 -2
The effective income tax rates for the second quarter and first six months of 2013 reflect benefits from reductions in tax reserves upon expiration of applicable statute of limitations. In addition, the effective tax rate for the first six months of 2013 reflects the favorable impact of tax legislation enacted in the first quarter of 2013, as well as a benefit of approximately $160 million associated with the resolution of a previously disclosed federal income tax issue.
Animal Health sales totaled $872 million for the second quarter of 2014, a 2 percent increase compared with the second quarter of 2013, including a 1 percent negative impact due to foreign exchange. The growth was primarily driven by BRAVECTO (fluralaner), a chewable tablet that kills fleas and ticks in dogs for up to 12 weeks, which launched in Europe and the United States, as well as higher sales in poultry and aqua products. This growth was partially offset by the loss of sales of ZILMAX (zilpaterol hydrochloride), a feed supplement for beef cattle. The company decided last year to voluntarily suspend sales of ZILMAX in the United States and Canada. Excluding the impact of the ZILMAX sales suspension, Animal Health sales increased 9 percent in the second quarter.
Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. On July 2, 2014, Santen Pharmaceutical Co., Ltd acquired certain ophthalmology assets from Merck & Co., Inc.
| Bid/Size | Ask/Size |
|---|---|
| -- / -- | -- / -- |
| Price Open | Previous Close |
|---|---|
| 56.58 | 56.74 |
| Day High | Day Low |
|---|---|
| 57.12 | 56.28 |
| 52wk High/Date | 52wk Low/Date |
|---|---|
| 59.84 / 5/1/2014 | 44.62 / 11/1/2013 |
| % off 52wk High | % off 52wk Low |
|---|---|
| -5.08% | 27.30% |
| Beta (5 Yr) | Market Capitalization |
|---|---|
| 0.4 | 166.0B Large Cap |
| Shares Outstanding | Volatility Avg |
|---|---|
| 2.9B | 16.34 |
| EPS(TTM) | P/E Ratio |
|---|---|
| 1.90 | 29.9 |
| Dividend Announcement | Dividend Yield |
|---|---|
| 7/23/2014 | 3.10% |
| Ex-Date | Date of Record |
|---|---|
| 9/11/2014 | 9/15/2014 |
| Payable | Payable Date |
|---|---|
| 0.44 - QRTR | 10/7/2014 |
| Peers | |
|---|---|
MRK Merck & Co Inc | 13.49% |
Johnson & Johnson | 9.07% |
Pfizer Inc. | -5.78% |
Eli Lilly and Co | 18.98% |
Abbott Laboratories | 9.65% |
MRK Merck & Co Inc | 3.10% |
Johnson & Johnson | 2.80% |
Pfizer Inc. | 3.60% |
Eli Lilly and Co | 3.23% |
Abbott Laboratories | 2.09% |
MRK Merck & Co Inc | 0.11% |
Johnson & Johnson | -0.19% |
Pfizer Inc. | 0.56% |
Eli Lilly and Co | -0.62% |
Abbott Laboratories | -0.21% |